Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Over the last 12 months, insiders at Benitec Biopharma Inc. have bought $819,816 and sold $0 worth of Benitec Biopharma Inc. stock.
On average, over the past 5 years, insiders at Benitec Biopharma Inc. have bought $409,912 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: SUVRETTA CAPITAL MANAGEMENT, LLC () — $819,816.
The last purchase of 42,000 shares for transaction amount of $403,200 was made by SUVRETTA CAPITAL MANAGEMENT, LLC () on 2024‑12‑03.
2024-12-03 | 42,000 0.1737% | $9.60 | $403,200 | +17.55% | ||||
2024-11-20 | 27,436 0.113% | $10.22 | $280,396 | +1.88% | ||||
2024-11-19 | 14,000 0.0584% | $9.73 | $136,220 | -2.16% | ||||
2023-08-11 | director | 51,813 <0.0001% | $0.00 | $5 | +26.33% | |||
2023-08-11 | Executive Director | 25,907 <0.0001% | $0.00 | $3 | +26.33% |